Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics.

Journal: Nature communications
PMID:

Abstract

Characterizing the human leukocyte antigen (HLA) bound ligandome by mass spectrometry (MS) holds great promise for developing vaccines and drugs for immune-oncology. Still, the identification of non-tryptic peptides presents substantial computational challenges. To address these, we synthesized and analyzed >300,000 peptides by multi-modal LC-MS/MS within the ProteomeTools project representing HLA class I & II ligands and products of the proteases AspN and LysN. The resulting data enabled training of a single model using the deep learning framework Prosit, allowing the accurate prediction of fragment ion spectra for tryptic and non-tryptic peptides. Applying Prosit demonstrates that the identification of HLA peptides can be improved up to 7-fold, that 87% of the proposed proteasomally spliced HLA peptides may be incorrect and that dozens of additional immunogenic neo-epitopes can be identified from patient tumors in published data. Together, the provided peptides, spectra and computational tools substantially expand the analytical depth of immunopeptidomics workflows.

Authors

  • Mathias Wilhelm
    Chair for Proteomics and Bioanalytics, TU Muenchen, Freising 85354, Germany.
  • Daniel P Zolg
    Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.
  • Michael Graber
    Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.
  • Siegfried Gessulat
    Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
  • Tobias Schmidt
    Jena University Hospital, Jena, Germany.
  • Karsten Schnatbaum
    JPT Peptide Technologies GmbH, Berlin, Germany.
  • Celina Schwencke-Westphal
    Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, School of Medicine, Technical University of Munich (TUM), Munich, Germany.
  • Philipp Seifert
    Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, School of Medicine, Technical University of Munich (TUM), Munich, Germany.
  • Niklas de Andrade Krätzig
    Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technical University of Munich (TUM), Munich, Germany.
  • Johannes Zerweck
    JPT Peptide Technologies GmbH, Berlin, Germany.
  • Tobias Knaute
    JPT Peptide Technologies GmbH, Berlin, Germany.
  • Eva Bräunlein
    Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, School of Medicine, Technical University of Munich (TUM), Munich, Germany.
  • Patroklos Samaras
    Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
  • Ludwig Lautenbacher
    Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.
  • Susan Klaeger
    Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Holger Wenschuh
    JPT Peptide Technologies GmbH, Berlin, Germany.
  • Roland Rad
    Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technical University of Munich (TUM), Munich, Germany.
  • Bernard Delanghe
    Thermo Fisher Scientific, Bremen, Germany.
  • Andreas Huhmer
    Thermo Fisher Scientific, San Jose, CA, USA.
  • Steven A Carr
    Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Karl R Clauser
    Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Angela M Krackhardt
    Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, School of Medicine, Technical University of Munich (TUM), Munich, Germany.
  • Ulf Reimer
    JPT Peptide Technologies GmbH, Berlin, Germany.
  • Bernhard Kuster
    Chair for Proteomics and Bioanalytics, TU Muenchen, Freising 85354, Germany; German Cancer Consortium (DKTK), Munich, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Center for Integrated Protein Science Munich, Munich, Germany; Bavarian Biomolecular Mass Spectrometry Center, Technische Universität München, Freising, Germany.